

EDITOR-IN-CHIEF L. Maximilian Buja, MD Dept. of Pathology and Laboratory Medicine McGovern Medical School The University of Texas Health Scienc Center at Houston (UTHealth) Houston, TX, USA

SENIOR ASSOCIATE EDITOR

Giulia M. Ottaviani, MD, PhD

ASSOCIATE EDITORS

Jagdish W. Butany, MBBS, MS, FRCPC Avrum I. Gotlieb, MD, CM, FRCPC Richard N. Mitchell, MD, PhD Claudia Pedroza, PhD Jeffrey E. Saffitz, MD, PhD Barbara Sampson, MD, PhD Frederick J. Schoen, MD, PhD James R. Stone, MD, PhD Gaetano Thiene, MD John P. Veinot, MD Renu Virmani, MD

ASSOCIATE EDITOR: SOCIAL MEDIA Melanie C. Bois, MD

CONSULTING EDITORS

Michael C. Fishbein, MD Michael A. Gimbrone, Jr, MD Ali J. Marian, MD Bruce McManus, MD, PhD Charles E. Murry, MD, PhD

EDITORIAL ASSISTANT Sarah Keith

FORMER EDITORS Jagdish W. Butany, MBBS, MS, FCRPC Stephen M. Factor, MD Avrum I. Gotlieb, MD, CM, FRCPC

CORNOTES EDITOR James B. Atkinson, MD

SOCIETY FOR CVP WEBMASTER Marc Halushka, MD

SOCIETY FOR CVP PUBLICATIONS COMMITTEE CHAIR Richard N. Mitchell, MD, PhD June 28, 2022

Members of the Editorial Board

The University of Texas Health Science Members of the Society for Cardiovascular Pathology

I am very pleased to share with you some great news we have received from our Elsevier publisher, Ian Blackford.

Cardiovascular Pathology's Impact Factor for 2021 has increased to 3.975! "This is a fantastic increase from 2.185." "Congratulations on this great achievement!"

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. So our latest impact factor measures citations received in 2021 for papers published in CVP in 2019 and 2020.

Ian Blackford has committed to performing an analysis of the data within the next several days. My thinking is that this almost doubling of our Impact Factor is closely linked to our proactive approach to publication of novel and insightful articles delving into the pathology of COVID-19 as well as a general commitment to high standards for selective acceptance of manuscripts vetted for scientific merit.

I want to thank members of the Editorial Board and the Society for their commitment to the Journal. Now we need to build on this accomplishment to make CVP a journal of choice for submission of high quality work and an increasingly recognized impactful source of information pertaining to cardiovascular disease.

Sincerely,

L. Maximilian Buja, MD Editor-in-Chief Cardiovascular Pathology

CARDIOVASCULAR PATHOLOGY